EGFR and non-small cell lung carcinoma: As pleural effusion fluid sampling is usually easy, non-invasive, and repeatable, we hypothesised that tumour-derived DNA in the pleural effusion fluid of NSCLC patients would be a source of useful information on the status of the EGFR gene and could allow prediction of the response to gefitinib.